10-Q: Retractable Technologies Reports Q3 2024 Results Amidst Tariff Challenges

Retractable Technologies experienced a net loss in Q3 2024, impacted by increased costs and new tariffs, despite a rise in unit sales.

Summary

• Retractable Technologies reported a net loss of $1.92 million for the third quarter of 2024, compared to a net loss of $4.06 million in the same period of 2023.
• The company's net sales were $10.35 million, essentially flat compared to $10.34 million in the third quarter of 2023.
• Cost of manufactured product increased significantly by 81.6% due to higher sales volume and increased domestic production costs.
• The gross profit margin decreased from 41.8% to -0.1% due to lower average selling prices and increased production costs.
• Operating expenses remained relatively stable, decreasing slightly by 2.6%.
• The company recognized an unrealized gain of $1.5 million on debt and equity securities.
• A significant change in valuation allowance on the deferred tax asset resulted in a tax benefit of $31 thousand for the quarter.
• For the nine months ended September 30, 2024, the net loss was $15.66 million, compared to a net loss of $6.94 million for the same period in 2023.
• The company's net sales for the first nine months of 2024 were $23.98 million, down from $29.31 million in the same period of 2023.
• The company has incurred $568 thousand in tariff expenses to date and expects to incur a total of approximately $1.5 million in tariff expenses through February 2025.
• The company is shifting a larger portion of manufacturing to its domestic facility to mitigate the impact of tariffs.

Sentiment

Score: 3

Explanation: The document presents a challenging financial picture for Retractable Technologies, with significant losses, declining gross profit margins, and the looming threat of tariffs. While the company is taking steps to mitigate these challenges, the overall sentiment is negative due to the severity of the financial impact and the uncertainty surrounding the company's ability to overcome these obstacles.

Positives

• Domestic unit sales increased by 29.6% in the third quarter of 2024.
• The company recognized an unrealized gain of $1.5 million on debt and equity securities in Q3 2024.
• The company is actively working to mitigate the impact of tariffs by shifting production to its domestic facility.
• The company has a Technology Investment Agreement (TIA) with the U.S. government which has provided significant funding for expanding domestic production.

Negatives

• The company experienced a net loss of $1.92 million in Q3 2024, and $15.66 million for the first nine months of 2024.
• Gross profit margin decreased significantly from 41.8% to -0.1% in Q3 2024.
• International revenues decreased by approximately 23.8% in Q3 2024 and 62.6% for the first nine months of 2024.
• The company has incurred $568 thousand in tariff expenses to date and expects to incur a total of approximately $1.5 million in tariff expenses through February 2025.
• The company recorded a provision for income taxes of $8.4 million for the first nine months of 2024, primarily due to a valuation allowance on the deferred tax asset.
• The company is facing increased production costs and higher period costs associated with increased domestic production activities.

Risks

• The newly enacted 100% tariffs on imported syringes and needles from China are expected to have a material negative impact on the company's results of operations and financial position.
• The company's ability to mitigate the impact of tariffs by shifting production to its domestic facility is uncertain and may be expensive.
• The company's lawsuit to exempt its payment of tariffs may not succeed.
• The company is facing increased production costs and higher period costs associated with increased domestic production activities.
• The company's reliance on Chinese manufacturers for a significant portion of its products exposes it to supply chain risks.
• The company's domestic customers may have retained products provided for vaccination purposes in inventory, leading to a decrease in sales.
• The company's financial performance is subject to market fluctuations and changes in demand for its products.
• The company's ability to maintain liquidity is dependent on its ability to generate revenue and manage expenses.

Future Outlook

The company expects tariffs to materially increase costs in future periods and is working to mitigate the impact by shifting production to its domestic facility. The company believes it has adequate means to meet its short-term needs to fund operations for at least 12 months from the date of issuance of the financial statements. The company expects to spend approximately $1 million over the next few months using existing cash reserves to convert a portion of its domestic equipment to align to its plan to produce more units at its U.S. facility. The company believes its liquidity will decline materially over the next 1-3 years but expects that it may be able to satisfy its long-term cash requirements using a combination of cash and liquidation of its equity investments.

Management Comments

• Management believes the institutions where cash balances are maintained are of high credit quality.
• Management is responsible for directing investment activity based on current economic conditions.
• Management considers any exposure from concentrations of credit risks to be limited.
• Management reviews factors quarterly to determine if any adjustments are needed to the allowance for credit losses.
• Management is responsible for developing estimates for amounts reported as assets and liabilities, and revenues and expenses in conformity with U.S. generally accepted accounting principles (GAAP).
• Management believes that it has sufficient historical data, and a firm basis for establishing reserves for contractual obligations.
• Management concluded that, as of September 30, 2024, the company's disclosure controls and procedures were effective.

Industry Context

The medical device industry is facing increased scrutiny and cost pressures due to global supply chain disruptions and trade policies. The imposition of tariffs on medical devices imported from China is a significant challenge for companies like Retractable Technologies, which rely on Chinese manufacturers for a substantial portion of their products. The company's efforts to increase domestic production are in line with a broader trend of reshoring manufacturing to mitigate supply chain risks.

Comparison to Industry Standards

• Retractable Technologies' gross profit margin of -0.1% in Q3 2024 is significantly below the industry average for medical device manufacturers, which typically ranges from 40% to 60%.
• Companies like Becton Dickinson (BD) and Medtronic, which are major players in the medical device industry, generally have higher gross profit margins due to their scale and diversified product portfolios.
• The company's reliance on Chinese manufacturers for 90% of its products is higher than many of its competitors, which have more diversified supply chains.
• The company's decision to increase domestic production is a strategic move to reduce its reliance on Chinese manufacturers and mitigate the impact of tariffs, which is a common strategy among companies facing similar challenges.
• The company's legal action against the USTR is a unique situation, as most companies in the industry tend to adapt to trade policies rather than challenge them directly.

Legal Proceedings

• The company is involved in a lawsuit against Locke Lord, LLP and Roy Hardin, with a new trial date set for June 2, 2025.
• The company has filed a lawsuit against the United States of America, the Office of the United States Trade Representative, and other defendants, seeking an injunction on recently enacted tariffs.

Related Party Transactions

• The company has a license agreement with Thomas J. Shaw, which includes quarterly royalty payments and a share of royalties from sublicensees.

Stakeholder Impact

• Shareholders are negatively impacted by the company's net losses and declining gross profit margins.
• Employees may be impacted by potential changes in manufacturing operations and workforce adjustments.
• Customers may be impacted by potential price increases due to tariffs.
• Suppliers may be impacted by changes in the company's sourcing strategy.
• Creditors may be impacted by the company's declining liquidity.

Next Steps

• The company will continue to monitor the impact of tariffs on its operations and financial position.
• The company will continue to shift a larger portion of manufacturing to its domestic facility.
• The company will continue to pursue its lawsuit against the USTR.
• The company will continue to evaluate the appropriate mix of products manufactured domestically and those manufactured in China.
• The company will continue to monitor its cash flow and liquidity.
• The company expects to spend approximately $1 million over the next few months using existing cash reserves to convert a portion of its domestic equipment.

Key Dates

Keywords

tariffs, syringes, medical devices, manufacturing, financial results, net loss, gross profit, domestic production, international sales, valuation allowance, deferred tax asset, Technology Investment Agreement